First Turn Management LLC Sells 64,923 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

First Turn Management LLC lessened its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 4.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,451,037 shares of the company’s stock after selling 64,923 shares during the quarter. ORIC Pharmaceuticals comprises 2.4% of First Turn Management LLC’s holdings, making the stock its 20th biggest position. First Turn Management LLC owned 2.06% of ORIC Pharmaceuticals worth $14,873,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of ORIC. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of ORIC Pharmaceuticals by 162.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company’s stock worth $36,000 after buying an additional 3,188 shares during the last quarter. Quest Partners LLC grew its position in ORIC Pharmaceuticals by 253.2% during the second quarter. Quest Partners LLC now owns 10,378 shares of the company’s stock valued at $73,000 after buying an additional 7,440 shares during the period. Creative Planning acquired a new stake in shares of ORIC Pharmaceuticals in the third quarter valued at about $116,000. China Universal Asset Management Co. Ltd. grew its position in shares of ORIC Pharmaceuticals by 71.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 13,568 shares of the company’s stock valued at $139,000 after purchasing an additional 5,646 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of ORIC Pharmaceuticals in the second quarter valued at about $153,000. Institutional investors own 95.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on ORIC shares. Wedbush reaffirmed an “outperform” rating and set a $20.00 target price on shares of ORIC Pharmaceuticals in a research note on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Monday, September 23rd. Stifel Nicolaus initiated coverage on shares of ORIC Pharmaceuticals in a report on Friday, September 6th. They issued a “buy” rating and a $20.00 target price on the stock. Oppenheimer lowered their price objective on shares of ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 price objective on shares of ORIC Pharmaceuticals in a report on Monday, November 4th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $18.29.

ORIC Pharmaceuticals Trading Up 0.7 %

NASDAQ:ORIC opened at $8.56 on Tuesday. The business’s 50-day simple moving average is $9.69 and its 200-day simple moving average is $9.33. ORIC Pharmaceuticals, Inc. has a fifty-two week low of $6.33 and a fifty-two week high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Tuesday, November 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.01). As a group, sell-side analysts anticipate that ORIC Pharmaceuticals, Inc. will post -1.85 EPS for the current year.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.